ID Source | ID |
---|---|
PubMed CID | 9577136 |
CHEMBL ID | 1099026 |
SCHEMBL ID | 5526339 |
MeSH ID | M0174664 |
Synonym |
---|
[(e)-1-(2-pyridyl)ethylideneamino]urea |
(1e)-1-(2-pyridinyl)ethanone semicarbazone |
apsc |
2-acetylpyridine semicarbazone |
2-acetylpyridine-semicarbazone |
hapsc |
CHEMBL1099026 |
hydrazinecarboxamide, 2-(1-(2-pyridinyl)ethylidene)- |
14534-93-1 |
AKOS015992570 |
SCHEMBL5526339 |
120446-04-0 |
3N-005 |
[(e)-[1-(pyridin-2-yl)ethylidene]amino]urea |
2-[(e)-1-(2-pyridinyl)ethylidene]-1-hydrazinecarboxamide |
2-((e)-1-(2-pyridinyl)ethylidene)-1-hydrazinecarboxamide |
mfcd00832644 |
[(e)-1-pyridin-2-ylethylideneamino]urea |
2-acetylpyridine semi-carbazone |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID478787 | Selectivity index, ratio of IC50 for mouse J774 cells to MIC for Mycobacterium tuberculosis H37Rv | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. |
AID478785 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurine microtiter assay | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. |
AID478786 | Cytotoxicity against mouse J774 cells after 24 hrs by resazurin assay | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: anti-Mycobacterium tuberculosis activity and cytotoxicity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 3 (60.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (20.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |